Al-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.
Al-Ola A. Abdallah, MD, assistant professor, Hematologic Malignancies and Cellular Therapeutics, director, Plasma Cell Disorder Clinic, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, discusses interim results from an ongoing phase 1 trial of HPN217 (NCT04184050) in heavily pretreated patients with relapsed/refractory multiple myeloma.
The study is currently investigating the safety, tolerability and activity of the half-life extended BCMA-directed T-cell engager HPN217 through step-up dosing in patients who have received 3 or more prior immunotherapies.
Updated efficacy data presented at the 2022 ASH Annual Meeting showed that HPN217 elicited an overall response rate of 77% in patients receiving higher doses of 12 mg to 24 mg, Abdallah says. Of these patients, 46% experienced a very good partial response or greater. Furthermore, duration of response (DOR) was sustained up to 12 months for patients who remained on treatment for 9 months or more, Abdallah notes.
As BCMA-directed therapies typically exhibit deeper and more durable responses over time, researchers believe that the DOR for HPN217 will improve as patient enrollment and follow-up continues, Abdallah concludes.